Several post hoc analyses of these studies led to the hypothesis that hyporesponsiveness to ESA (i.e., high doses of ESA required to correct Hb levels) was a major determinant of negative outcomes in patients with CKD [12–14]. This evidence concerns the gene GSTM1 and chronic kidney disease.